Clinical Diagnostic Values of C1q/TNF-Related Protein-3 for Polycystic Ovary Syndrome Women with Insulin Resistance

Abstract

Polycystic ovary syndrome (PCOS) is the most common disease caused by complex endocrine and metabolic abnormalities in women. Insulin resistance is considered an important pathophysiological factor in the pathogenesis of PCOS. Here we investigated the clinical values of C1q/TNF-related protein-3 (CTRP3) as predictive factor for insulin resistance. Our study included 200 patients with PCOS, among which 108 had insulin resistance. Serum CTRP3 levels were measured using enzyme-linked immunosorbent assay. Predictive values of CTRP3 for insulin resistance was analyzed using receiver operating characteristic (ROC) analysis. Correlations of CTRP3 to insulin levels, obesity measurements and blood lipid levels were determined using Spearman’s correlation analysis. Our data suggested that PCOS patients with insulin resistance had a higher obesity, lower high-density lipoprotein cholesterol, higher total cholesterol, higher insulin levels and lower CTRP3 levels. CTRP3 had a high sensitivity (72.22%) and specificity (72.83%). CTRP3 significantly correlated to insulin levels, body mass index, waist-to-hip ratio, high-density lipoprotein, and total cholesterol levels. The predictive value of CTRP3 in PCOS patients with insulin resistance was supported by our data. Our findings suggest that CTRP3 is involved in the pathogenesis and insulin resistance of PCOS, which indicates its value as an indicator for the PCOS diagnosis.

Keywords

lipoprotein - obesity - metabolic syndrome - insulin resistance - diabetes - C1q/TNF-related protein-3

• References

• 1 Escobar-Morreale HF.. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270-284
• 2 Louwers YV, Laven JSE.. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health 2020; 14: 2633494120911038
• 3 Zhu J, Pujol-Gualdo N, Wittemans LBL. et al. Evidence from men for ovary-independent effects of genetic risk factors for polycystic ovary syndrome. J Clin Endocrinol Metab 2022; 107: e1577-e1587
• 4 Mizgier M, Jarząbek-Bielecka G, Opydo-Szymaczek J. et al. Risk factors of overweight and obesity related to diet and disordered eating attitudes in adolescent girls with clinical features of polycystic ovary syndrome. J Clin Med 2020; 9: 3041
• 5 Wang J, Wu D, Guo H. et al. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome. Life Sci 2019; 236: 116940
• 6 Miao C, Fang X, Zhang Q.. Letter to the editor from Chenyun Miao et al.: Effect of diet on insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2021; 106: e2378-e2379
• 7 Yaribeygi H, Farrokhi FR, Butler AE. et al. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol 2019; 234: 8152-8161
• 8 Mehrabani S, Arab A, Karimi E. et al. Blood circulating levels of adipokines in polycystic ovary syndrome patients: a systematic review and meta-analysis. Reprod Sci 2021; 28: 3032-3050
• 9 Taylor EB.. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci 2021; 135: 731-752
• 10 Yu F, Zhou X, Li Z. et al. Diagnostic significance of plasma levels of novel adipokines in patients with symptomatic intra-and extracranial atherosclerotic stenosis. Front Neurol 2019; 10: 1228
• 11 Yanai H, Yoshida H.. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci 2019; 20: 1190
• 12 Choi HM, Doss HM, Kim KS.. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci 2020; 21: 1219
• 13 Kou H, Deng J, Gao D. et al. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. Clin Exp Hypertens 2018; 40: 656-663
• 14 Wang D, Zhang Y, Shen C.. Research update on the association between SFRP5, an anti-inflammatory adipokine, with obesity, type 2 diabetes mellitus and coronary heart disease. J Cell Mol Med 2020; 24: 2730-2735
• 15 Moradi N, Najafi M, Sharma T. et al. Circulating levels of CTRP3 in patients with type 2 diabetes mellitus compared to controls: a systematic review and meta-analysis. Diabetes Res Clin Pract 2020; 169: 108453
• 16 Guo B, Zhuang T, Xu F. et al. New insights into implications of CTRP3 in obesity, metabolic dysfunction, and cardiovascular diseases: potential of therapeutic interventions. Front Physiol 2020; 11: 570270
• 17 Ahmed SF, Shabayek MI, Abdel Ghany ME. et al. Role of CTRP3, CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females. PLoS One 2018; 13: e0208038
• 18 Ren M, Liu J, Zhang Y. et al. Effects of different ovulation induction regimens on sex hormone levels and serum CTRP3 and CTRP15 levels in patients with polycystic ovary syndrome (PCOS). Biomed Res Int 2022; 6027878
• 19 Gulumsek E, Pekoz BC, Koc AS. et al. Liver stiffness is increased in polycystic ovary syndrome and related with complement C1q/tumor necrosis factor-related protein 3 levels: a point shear wave elastography study. Ultrasound Q 2020; 37: 133-137
• 20 Tan BK, Chen J, Hu J. et al. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98: E1891-E1900
• 21 Tripathy P, Sahu A, Sahu M. et al. Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes. Eur J Obstet Gynecol Reprod Biol 2018; 224: 60-65
• 22 Sun Y-F, Zhang J, Xu Y-M. et al. High BMI and insulin resistance are risk factors for spontaneous abortion in patients with polycystic ovary syndrome undergoing assisted reproductive treatment: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2020; 11: 592495
• 23 Peterson JM, Wei Z, Wong GW.. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem 2010; 285: 39691-39701
• 24 Lin J, Liu Q, Zhang H. et al. C1q/Tumor necrosis factor-related protein-3 protects macrophages against LPS-induced lipid accumulation, inflammation and phenotype transition via PPARγ and TLR4-mediated pathways. Oncotarget 2017; 8: 82541
• 25 Yang Y, Li Y, Ma Z. et al. A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection. Prog Lipid Res 2016; 64: 170-177
• 26 Legro RS.. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. Stuttgart: Thieme Medical Publishers; 2012: 496-506
• 27 Gambineri A, Pelusi C, Vicennati V. et al. Obesity and the polycystic ovary syndrome. Int J Obes 2002; 26: 883-896
• 28 Hoeger K.. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 85-97
• 29 Li X, Jiang L, Yang M. et al. CTRP3 improves the insulin sensitivity of 3T3-L1 adipocytes by inhibiting inflammation and ameliorating insulin signalling transduction. Endokrynol Pol 2014; 65: 252-258
• 30 Chen T, Wang F, Chu Z. et al. Serum CTRP3 levels in obese children: a potential protective adipokine of obesity, insulin sensitivity and pancreatic β cell function. Diabetes Metab Syndr Obes Targets Therapy 2019; 12: 1923
• 31 Chen L, Qin L, Liu X. et al. CTRP3 alleviates Ox-LDL–induced inflammatory response and endothelial dysfunction in mouse aortic endothelial cells by activating the PI3K/Akt/eNOS pathway. Inflammation 2019; 42: 1350-1359
• 32 Peterson JM, Seldin MM, Wei Z. et al. CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol-Gastrointest Liver Physiol 2013; 305: G214-G224
• 33 Murayama MA, Kakuta S, Maruhashi T. et al. CTRP3 plays an important role in the development of collagen-induced arthritis in mice. Biochem Biophys Res Commun 2014; 443: 42-48